Diabetic-like retinopathy: Early and late intervention therapies in galactose-fed rats

Investigative Ophthalmology and Visual Science

Volumn 39, Issue 10, 1998, Pages 1933-1941

  Robison Jr , W Gerald ^a   Jacot, Jorge L ^a   Glover, Joel P ^b   Basso, Michael D ^a   Hohman, Tljomas C ^b  

^a NATIONAL EYE INSTITUTE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; GALACTOSE; MINALRESTAT; POLYOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY BASEMENT MEMBRANE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DIABETIC RETINOPATHY; DOSE TIME EFFECT RELATION; FEMALE; HISTOPATHOLOGY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ALDEHYDE REDUCTASE; ANIMALS; BASEMENT MEMBRANE; BLOOD GLUCOSE; DIABETIC RETINOPATHY; FEMALE; GALACTOSE; GALACTOSEMIAS; HEMOGLOBIN A, GLYCOSYLATED; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RETINAL VESSELS;

EID: 0031682698     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the devel-opment and progression of long-term complications in insulindependent diabetes mellitus. N EnglJMed. 1993:329:977-986.
2. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N EnglJ Med. 1993:329:30 4 -309.
3. Diabetes Control and Complications Trial (DCCT) Research Group. The relationship of glycémie exposure (HbAlc) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995:44: 968-983.
4. Engerman RL, Kern TS. Experimental galactosemia produces diabetic-like retinopathy. Diabetes. 1984:33:97-100.
5. Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Opbtbalmol. 1990:108:1301-1309.
6. Kador PF, Takahashi Y, Sato S, Wyman M. Amelioration of diabeteslike retinal changes in galactose-fed dogs. Preventive Meil. 1994; 23:717-721.
7. Frank RN, Keirn RJ, Kennedy A, Frank KW. Galactose-induced retinal capillary basement membrane thickening: prevention by sorbinil. Invest Opbtbalmol Vis Sci. 1983;24:1519-1524.
8. Kern TS, Engerman RL. Galactose-induced retinal microangiopathy in rats. Invest Opbtbalmol Vis Sci. 1995:36:490-496.
9. Frank RN, Amin R, Kennedy A, Hohman TC. An aldose reductase inhibitor and aminoguanidine both prevent vascular endothelial growth factor (VEGF) expression in long-term galactoscmic rats. Arch Opbtbalmol. 1997:115:1036-1047.
10. Robison WG Jr, Kador PF, Kinoshita JH. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science. 1983:221:1177-1179.
11. Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Opbtbalmol Vis Sci. 1989:30:2285-2292.
12. Robison WG Jr, Laver NM, Lou MF. The role of aldose reductase in diabetic retinopathy: prevention and intervention studies. Prog Retinal Eye Res. 1995:14:593-640.
13. Robison WG Jr, Laver NM, Jacot JL, Glover JP. Sorbinil prevention of diabetic-like retinopathy in the galactose-fed rat model. Invest Opbthahnol Vis Sci. 1995;36:2368-2380.
14. Robison WG Jr, Laver NM, Jacot JL, et al. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509. Invest Opbtbalmol Vis Sci. 1996:37:1149-1156.
15. Robison WG Jr, Laver NM, Jacot JL, Chandler ML, York B.M, Glover, JP. Efficacy of treatment after measurable diabeticlike retinopathy in galactose-fed rats. Invest Opbtbalmol Vis Sci. 1997:38:1066-1073.
16. Engerman RL, Kern TS. Retinopathy in galactosemic dogs continues to progress after cessation of galactoserm'a. Arch Opbtbalmol. 1995:113:355-358.
17. Malamas MS, Hohman TC, Millen J. Novel spirosuccinimide aldose reductase inhibitors derived from isoquinoline-l,3-diones: 2-[(4-bromo-2-fluoroplienyl)-methyl]-6-fluorospiro-[isoquinoIine-4(lH), 3′pyrrolidine]-l,2′,3,5′ (2H)-tetrone and congeners. J Meet Cbein. 1994:37:2043-2058.
18. Williamson JR, Kilo C. Current status of capillary basement-membrane disease in diabetes mellitus. Diabetes. 1977:26:65-75.
19. Robison WG Jr, Kador PF, Akagi Y, Kinoshita JH, Gonzalez R, Dvornik D. Prevention of basement membrane thickening in retinal capillaries by a novel inhibitor of aldose reductase, tolrestat. Diabetes. 1986;35:295-299.
20. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. Guide for the Care and Use of Laboratory Animals. Washington, DC: National Academy Press; 1996:1-125.
21. Neter J, Wasserman W, Kutner Mil. Applied Linear Statistical Models. Boston: RD Irwin; 1992:113-151.
22. Carroll RJ, Ruppert D. Transformation and Weighting Regression. New York: Chapman and Hall; 1988:174-224.
23. McCaleb ML, McKean ML, Hohman TC, Laver N, Robison WG Jr. Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. Diabetologia. 1991:34:695-701.
24. Engerman RL, Kern TS. Progression of incipient diabetic retinopathy during good glycémie control. Diabetes. 1987:36:808-812.